CIRCADIAN TIME-DEPENDENT RESPONSE OF CHILDHOOD LYMPHOBLASTIC-LEUKEMIA TO CHEMOTHERAPY - A LONG-TERM FOLLOW-UP-STUDY OF SURVIVAL

被引:48
作者
RIVARD, GE [1 ]
INFANTERIVARD, C [1 ]
DRESSE, MF [1 ]
LECLERC, JM [1 ]
CHAMPAGNE, J [1 ]
机构
[1] MCGILL UNIV,SCH OCCUPAT HLTH,MONTREAL H3A 2T5,QUEBEC,CANADA
关键词
CHRONOPHARMACOLOGY; LEUKEMIA; CHEMOTHERAPY; 6-MERCAPTOPURINE;
D O I
10.3109/07420529309073888
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The evolution of 1 18 children treated for acute lymphoblastic leukemia between 1976 and 1984, and followed until 1991, was reviewed. Maintenance chemotherapy consisted of daily 6-mercaptopurine (6-MP), weekly methotrexate (MTX), and monthly vincristine and prednisone. Eighty-two children took 6-MP and MTX in the morning, and 36 took them in the evening. Disease-free survival, as determined by Kaplan-Meier analysis, was better for children on evening chemotherapy. Regression analysis (Cox proportional hazards model, with evening versus morning schedule as exposure variable, and age at diagnosis, leucocytosis at diagnosis, and sex as covariates) showed that for those surviving free of disease for longer than 78 weeks, the risk of relapse was 2.56 times greater for the morning schedule than for the evening one.
引用
收藏
页码:201 / 204
页数:4
相关论文
共 12 条
[1]  
BALIS FM, 1989, AM J PEDIAT HEMATOL, V11, P324
[2]  
COX DR, 1972, J R STAT SOC B, V34, P187
[3]   THE CLINICAL-APPLICATION OF CHRONOBIOLOGY TO ONCOLOGY [J].
HRUSHESKY, WJM .
AMERICAN JOURNAL OF ANATOMY, 1983, 168 (04) :519-542
[4]  
KACHERGENE NB, 1972, PEDIATRICS, V2, P81
[5]  
LANGEVIN AM, 1987, LANCET, V2, P505
[6]  
MAUER AM, 1965, BLOOD-J HEMATOL, V26, P1
[7]   BLOOD LEUKOCYTE ENZYMES .3. DIURNAL RHYTHM OF ACTIVITY IN ISOLATED LYMPHOCYTES OF NORMAL SUBJECTS AND CHRONIC LYMPHATIC LEUKEMIA PATIENTS [J].
RAMOT, B ;
BROKSIMONI, F ;
CHWEIDAN, E ;
ASHKENAZI, YE .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 34 (01) :79-85
[8]  
RIVARD GE, 1985, LANCET, V2, P1264
[9]  
RIVARD GE, 1989, AM J PEDIAT HEMATOL, V11, P402
[10]  
ROBISON LL, 1980, AM J PEDIAT HEMATOL, V2, P5013